Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Their Functional Consequences News

Their Functional Consequences News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Their Functional Consequences. Real-time updates on events, politics, business and more.

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

January 6, 2022
TOKYO, Jan 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of
United Kingdom United States Eisai Co Ltd Roivant Development Code Biomedicine Inc Roivant Sciences Ltd
Source: finanznachrichten.de

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

January 6, 2022
TOKYO, Jan 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV). H3B-8800 (Roivant's Development Code: RVT-2001) is a splicing modulator compound, discovered by Eisai's...
United Kingdom United States Eisai Co Ltd Roivant Development Code Biomedicine Inc Roivant Sciences Ltd
Source: asiaone.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science